Cover Image
市場調查報告書

靜脈血栓症:開發平台分析

Venous (Vein) Thrombosis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 321937
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
靜脈血栓症:開發平台分析 Venous (Vein) Thrombosis - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 80 Pages
簡介

靜脈血栓症是深部靜脈形成的血栓。症狀有皮膚顏色改變(變紅)、腳部疼痛、腳部腫(浮腫)、接觸皮膚可感到溫熱等。因素有老化、吸煙、血液凝固障礙的遺傳、受傷和手術、癌症、發炎性腸道疾病、心臟衰竭等。

根據由於本報告提供靜脈血栓症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃相關資訊等,再加上最新的新聞和發表等。

簡介

  • 調查範圍

靜脈血栓症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai
  • F. Hoffmann-La Roche Ltd.
  • Generex Biotechnology Corporation
  • GlycoMimetics, Inc.
  • Merrion Pharmaceuticals Plc
  • Regado Biosciences, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AB-012
  • apixaban
  • BAY-1213790
  • BMS-593214
  • E-5539
  • ER-410660
  • fondaparinux sodium
  • GMI-1271
  • ichorcumab
  • Low Molecular Weight Heparin
  • NPB-06
  • REG-2
  • rivaroxaban
  • RNAi Oligonucleotide for DVT
  • Small Molecules for Hematological Disorders and Cancer
  • TRX-1

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7342IDB

Summary

Global Markets Direct's, 'Venous (Vein) Thrombosis - Pipeline Review, H2 2015', provides an overview of the Venous (Vein) Thrombosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous (Vein) Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous (Vein) Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Venous (Vein) Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Venous (Vein) Thrombosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Venous (Vein) Thrombosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Venous (Vein) Thrombosis Overview
  • Therapeutics Development
    • Pipeline Products for Venous (Vein) Thrombosis - Overview
    • Pipeline Products for Venous (Vein) Thrombosis - Comparative Analysis
  • Venous (Vein) Thrombosis - Therapeutics under Development by Companies
  • Venous (Vein) Thrombosis - Therapeutics under Investigation by Universities/Institutes
  • Venous (Vein) Thrombosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Venous (Vein) Thrombosis - Products under Development by Companies
  • Venous (Vein) Thrombosis - Products under Investigation by Universities/Institutes
  • Venous (Vein) Thrombosis - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Archemix Corp.
    • Astellas Pharma Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Generex Biotechnology Corporation
    • Johnson & Johnson
    • Laboratorios Farmaceuticos Rovi, S.A.
    • Merrion Pharmaceuticals Plc
    • Nihon Pharmaceutical Industry Co., Ltd.
  • Venous (Vein) Thrombosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide for DVT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • apixaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARC-15105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-1468240 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1213790 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-5539 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enoxaparin biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ER-410660 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fondaparinux sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fondaparinux sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-375 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NPB-06 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Hematological Disorders and Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Venous (Vein) Thrombosis - Recent Pipeline Updates
  • Venous (Vein) Thrombosis - Dormant Projects
  • Venous (Vein) Thrombosis - Discontinued Products
  • Venous (Vein) Thrombosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015
      • Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting
      • Jun 15, 2015: New Clinical Data Further Supporting the Positive Benefit Risk Profile of Bayer's Xarelto and Real Life Insights to be Presented at ISTH 2015
      • May 04, 2015: Bayer's Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis
      • Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents
      • Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits
      • Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
      • Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE
      • Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
      • Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Venous (Vein) Thrombosis, H2 2015
  • Number of Products under Development for Venous (Vein) Thrombosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Venous (Vein) Thrombosis - Pipeline by 3SBio Inc., H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Archemix Corp., H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Astellas Pharma Inc., H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Bayer AG, H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Eisai Co., Ltd., H2 2015
  • Venous (Vein) Thrombosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Generex Biotechnology Corporation, H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Johnson & Johnson, H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2015
  • Venous (Vein) Thrombosis - Pipeline by Nihon Pharmaceutical Industry Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Venous (Vein) Thrombosis Therapeutics - Recent Pipeline Updates, H2 2015
  • Venous (Vein) Thrombosis - Dormant Projects, H2 2015
  • Venous (Vein) Thrombosis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Venous (Vein) Thrombosis, H2 2015
  • Number of Products under Development for Venous (Vein) Thrombosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top